Article
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Cancer research - 15 Aug 2005
Blagosklonny Mikhail V, Trostel Shana, Kayastha Ganesh, Demidenko Zoya N, Vassilev Lyubomir T, Romanova Larisa Y, Bates Susan, Fojo Tito
Abstract excerpt
Mutant p53 is a cancer-specific target for pharmacologic intervention. We show that histone deacetylase inhibitors such as FR901228 and trichostatin A completely depleted mutant p53 in cancer cell lines. This depletion was preceded by induction of p53-regulated transcription. In cells with mutant p53 pretreated with histone deacetylase inhibitors, DNA damage further enhanced the p53 trans-function. Furthermore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.